Prevalence and clinical significance of nonorgan specific antibodies in patients with autoimmune thyroiditis as predictor markers for rheumatic diseases

被引:28
作者
Elnady, Basant M. [1 ,2 ]
Kamal, Naglaa M. [3 ,4 ]
Shaker, Raneyah H. M. [5 ]
Soliman, Amal F. [1 ]
Hasan, Waleed A. [1 ]
Alghamdi, Hamed A. [4 ,6 ]
Algethami, Mohammed M. [7 ,8 ]
Jajah, Mohamed Bilal [7 ,8 ]
机构
[1] Benha Univ, Benha Fac Med, Dept Phys Med & Rheumatol, Banha, Egypt
[2] Alhada Armed Forces Hosp, Dept Rheumatol, At Taif, Saudi Arabia
[3] Cairo Univ, Dept Pediat & Pediat Hepatol, Fac Med, Cairo, Egypt
[4] Alhada Armed Forces Hosp, Dept Pediat, At Taif, Saudi Arabia
[5] Benha Univ, Benha Fac Med, Dept Publ Hlth, Banha, Egypt
[6] Armed Forces Hosp, At Taif, Saudi Arabia
[7] Al Hada Armed Forces Hosp, Dept Pulmonol, At Taif, Saudi Arabia
[8] Al Hada Armed Forces Hosp, Dept Endocrinol, At Taif, Saudi Arabia
关键词
antidouble-stranded DNA; antiextractable-nuclear antigens; antinuclear antibodies; autoimmune thyroid diseases; rheumatoid factor; anticyclic-citrullinated peptides; SYSTEMIC-LUPUS-ERYTHEMATOSUS; AMERICAN-COLLEGE; MUSCULOSKELETAL CONDITIONS; CLASSIFICATION CRITERIA; AUTOANTIBODIES; ARTHRITIS; ASSOCIATIONS; DISORDERS; BURDEN; HEALTH;
D O I
10.1097/MD.0000000000004336
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Autoimmune diseases are considered the 3rd leading cause of morbidity and mortality in the industrialized countries. Autoimmune thyroid diseases (ATDs) are associated with high prevalence of nonorgan-specific autoantibodies, such as antinuclear antibodies (ANA), antidouble-stranded deoxyribonucleic acid (anti-dsDNA), antiextractable-nuclear antigens (anti-ENAs), rheumatoid factor (RF), and anticyclic-citrullinated peptides (anti-CCP) whose clinical significance is unknown.We aimed to assess the prevalence of various nonorgan-specific autoantibodies in patients with ATD, and to investigate the possible association between these autoantibodies and occurrence of rheumatic diseases and, if these autoantibodies could be considered as predictor markers for autoimmune rheumatic diseases in the future.This study had 2 phases: phase 1; in which 61 ATD patients free from rheumatic manifestations were assessed for the presence of these nonorgan-specific autoantibodies against healthy 61 control group, followed by 2nd phase longitudinal clinical follow-up in which cases are monitored systematically to establish occurrence and progression of any rheumatic disease in association to these autoantibodies with its influences and prognosis.Regarding ATD patients, ANA, anti-dsDNA, Anti-ENA, and RF were present in a percentage of (50.8%), (18%), (21.3%), and (34.4%), respectively, with statistically significance difference (P<0.5) rather than controls. Nearly one third of the studied group (32.8%) developed the rheumatic diseases, over 2 years follow-up. It was obvious that those with positive anti-dsDNA had higher risk (2.45 times) to develop rheumatic diseases than those without. There was a statistically significant positive linear relationship between occurrence of disease in months and (age, anti-dsDNA, anti-CCP, RF, and duration of thyroiditis). Anti-dsDNA and RF are the most significant predictors (P<0.0001).ATD is more associated with rheumatic diseases than previously thought. Anti-dsDNA, RF, and anti-CCP antibodies may be used as predictive screening markers of systemic lupus erythematosus and RA, with early referral to rheumatologists for close follow-up and early diagnoses for appropriate disease management of the disease, as early disease control will allow better quality of life.
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Sperm, nuclear, phospholipid, and red blood cell antibodies and isotype RF in infertile couples and patients with autoimmune rheumatic diseases
    Fichorova, R
    Nakov, L
    Baleva, M
    Nikolov, K
    Gegova, I
    AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 1996, 36 (06): : 309 - 316
  • [42] Prevalence of autoimmune diseases and clinical significance of autoantibody profile: Data from National Institute of Hygiene in Rabat, Morocco
    Missoum, Hakima
    Alami, Mohammed
    Bachir, Fatema
    Arji, Naima
    Bouyahya, Abdelhakim
    Rhajaoui, Mohammed
    El Aouad, Rajae
    Bakri, Youssef
    HUMAN IMMUNOLOGY, 2019, 80 (07) : 523 - 532
  • [43] Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases
    Pablos, Jose L.
    Abasolo, Lydia
    Alvaro-Gracia, Jose M.
    Blanco, Francisco J.
    Blanco, Ricardo
    Castrejon, Isabel
    Fernandez-Fernandez, David
    Fernandez-Gutierrez, Benjamin
    Galindo-Izquierdo, Maria
    Gonzalez-Gay, Miguel A.
    Manrique-Arija, Sara
    Mena Vazquez, Natalia
    Mera Varela, Antonio
    Retuerto, Miriam
    Seijas-Lopez, Alvaro
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (09) : 1170 - 1173
  • [44] Prevalence of vitamin D deficiency in patients with autoimmune rheumatic diseases visiting the rheumatology clinic at the National Referral Hospital, Bhutan
    Dorji, Sangay
    Yangchen, Sonam
    Chuki, Pem
    SAGE OPEN MEDICINE, 2024, 12
  • [45] DIAGNOSTIC AND PROGNOSTIC-SIGNIFICANCE OF DIFFERENT ANTINUCLEAR ANTIBODIES IN MORE THAN 1000 CONSECUTIVE ALBANIAN PATIENTS WITH RHEUMATIC DISEASES
    SULCEBE, G
    MORCKA, K
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 1992, 10 (03) : 255 - 261
  • [46] COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology
    Park, Jin Kyun
    Lee, Eun Bong
    Shin, Kichul
    Sung, Yoon-Kyoung
    Kim, Tae Hwan
    Kwon, Seong-Ryul
    Lee, Myeung Su
    Hong, Seung-Jae
    Choi, Byoong Yong
    Lee, Shin-Seok
    Back, Han Joo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (12) : 1 - 12
  • [47] Incidence of infection other than tuberculosis in patients with autoimmune rheumatic diseases treated with bDMARDs: a real-time clinical experience from India
    Chandrashekara, S.
    Shobha, Vineeta
    Rao, Vijay
    Desai, Anu
    Jois, Ramesh
    Dharmanand, B. G.
    Kumar, Sharath
    Kumar, Pradeep
    Dharmapalaiah, Chethana
    Mahendranath, Kurugodu Mathada
    Prasad, Shiva
    Daware, Manisha Ashwin
    Singh, Yogesh
    Karjigi, Uma
    Nagaraj, S.
    Anupama, K. R.
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (03) : 497 - 507
  • [48] The prevalence and clinical significance of anti-PUF60 antibodies in patients with idiopathic inflammatory myopathy
    Zhang, Ya-Mei
    Yang, Han-Bo
    Shi, Jing-Li
    Chen, He
    Shu, Xiao-Ming
    Lu, Xin
    Wang, Guo-Chun
    Peng, Qing-Lin
    CLINICAL RHEUMATOLOGY, 2018, 37 (06) : 1573 - 1580
  • [49] Prevalence and clinical significance of anti-MDA5 antibodies in European patients with polymyositis/dermatomyositis
    Ceribelli, A.
    Fredi, M.
    Taraborelli, M.
    Cavazzana, I.
    Tincani, A.
    Selmi, C.
    Chan, J. Y. F.
    Chan, E. K. L.
    Satoh, M.
    Franceschini, F.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (06) : 891 - 897
  • [50] Prevalence and clinical significance of antiprothrombin antibodies in patients with systemic lupus erythematosus or with primary antiphospholipid syndrome
    Muñoz-Rodríguez, FJ
    Reverter, JC
    Font, J
    Tàssies, D
    Cervera, R
    Espinosa, G
    Carmona, F
    Balasch, J
    Ordinas, A
    Ingelmo, M
    HAEMATOLOGICA, 2000, 85 (06) : 632 - 637